TXMD · Therapeuticsmd, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $393.0K | - | - | - | - | - | - | - | ($53.0K) | $437.0K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | ($53.0K) | $437.0K |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $1.49M | - | $1.58M | $1.55M | $1.32M | - | $1.23M | - | $1.59M | $2.78M |
| Total Operating Expenses | $1.45M | - | $1.65M | $1.65M | $1.46M | - | $2.67M | - | $1.72M | $2.91M |
| D&A | $94.0K | - | $96.0K | $96.0K | $133.0K | - | $128.0K | - | $0 | $0 |
| Operating Income | ($723.0K) | - | ($862.0K) | ($695.0K) | ($1.14M) | - | ($2.44M) | - | ($1.77M) | ($2.47M) |
| Interest Expense | - | - | - | - | - | - | - | - | $20.0K | $45.0K |
| Income Tax | - | - | - | - | ($32.0K) | - | - | - | - | - |
| Net Income | $95.0K | - | ($609.0K) | $551.0K | ($653.0K) | - | ($734.0K) | - | ($3.38M) | ($2.41M) |
| EPS - Basic | $0.01 | - | $0.01 | $0.05 | ($0.06) | - | ($0.09) | - | ($0.32) | ($0.24) |
| EPS - Diluted | $0.01 | - | ($0.05) | $0.05 | ($0.06) | - | ($0.09) | - | ($0.32) | ($0.24) |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.42M | $7.48M | $7.12M | $6.07M | $5.75M | $5.06M | $5.23M | $4.33M | $49.32M | $49.32M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $15.0K | $377.0K | $263.0K | $350.0K | $176.0K | $258.0K | $143.0K | $27.0K | $696.0K | $1.51M |
| Current Assets | $15.26M | $14.45M | $14.50M | $13.46M | $12.51M | $12.26M | $11.82M | $11.80M | $17.44M | $19.61M |
| Total Assets | $37.58M | $37.66M | $38.67M | $38.50M | $38.24M | $38.82M | $40.13M | $43.31M | $50.49M | $53.69M |
| Current Liabilities | $4.91M | $4.79M | $4.95M | $4.66M | $4.74M | $5.17M | $5.82M | $6.85M | $14.51M | $14.36M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $10.61M | $10.78M | $11.23M | $11.21M | $11.50M | $11.45M | $12.46M | $14.02M | $22.44M | $22.49M |
| Stockholders' Equity | $26.97M | $26.88M | $27.09M | $27.29M | $26.74M | $27.37M | $27.67M | $29.29M | $28.05M | $31.20M |
| Retained Earnings | ($952.30M) | ($952.39M) | ($951.77M) | ($951.92M) | ($952.48M) | ($951.82M) | ($951.47M) | ($949.64M) | ($948.76M) | ($945.38M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $944.0K | - | - | - | ($229.0K) | - | - | - | - | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | 100.0% | 100.0% |
| Operating margin | -184.0% | - | - | - | - | - | - | - | 3345.3% | -565.7% |
| EBITDA margin | -160.1% | - | - | - | - | - | - | - | 3345.3% | -565.7% |
| Net margin | 24.2% | - | - | - | - | - | - | - | 6373.6% | -552.4% |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 379.4% | - | - | - | - | - | - | - | -3000.0% | 636.4% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | 0.3% | - | -1.6% | 1.4% | -1.7% | - | -1.8% | - | -6.7% | -4.5% |
| Return on equity | 0.4% | - | -2.2% | 2.0% | -2.4% | - | -2.7% | - | -12.0% | -7.7% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.11 | 3.02 | 2.93 | 2.89 | 2.64 | 2.37 | 2.03 | 1.72 | 1.20 | 1.37 |
| Quick ratio | 3.11 | 3.02 | 2.93 | 2.89 | 2.64 | 2.37 | 2.03 | 1.72 | 1.20 | 1.37 |
| Cash ratio | 1.71 | 1.56 | 1.44 | 1.30 | 1.21 | 0.98 | 0.90 | 0.63 | 3.40 | 3.43 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | -88.7x | -54.9x |
| Equity multiplier | 1.39 | 1.40 | 1.43 | 1.41 | 1.43 | 1.42 | 1.45 | 1.48 | 1.80 | 1.72 |
| Liabilities / Assets | 0.28 | 0.29 | 0.29 | 0.29 | 0.30 | 0.29 | 0.31 | 0.32 | 0.44 | 0.42 |
| Efficiency | ||||||||||
| Asset turnover | 0.01 | - | - | - | - | - | - | - | -0.00 | 0.01 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 202.0x | - | - | 23.2x | - | - | - | - | - | - |
| P / B | 0.0x | - | 0.5x | 0.5x | 0.4x | - | 0.7x | - | 1.2x | 1.3x |
| P / S | 0.1x | - | - | - | - | - | - | - | - | 96.3x |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | -100.3% | -98.5% |
| Revenue CAGR (3y) | -1.9% | - | - | - | - | - | - | - | - | -65.6% |
| Revenue CAGR (5y) | -54.4% | - | - | - | - | - | - | - | - | -36.6% |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | -98.2% |
| Operating income growth (YoY) | 36.7% | - | - | 71.5% | - | - | 1.3% | - | 91.5% | 86.9% |
| Net income growth (YoY) | - | - | - | - | - | - | 69.6% | - | 88.3% | - |
| EPS growth (YoY) | - | - | - | - | - | - | 62.5% | - | 89.8% | 95.6% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 0.9% | -1.8% | - | -1.4% | - | -6.5% | -11.3% | -16.7% | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-12-31.
Product / service
$1.30M totalLicense$1.30M · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing TherapeuticsMD against the 5 most active filers in the same SIC group.